HGH Frag

HGH Frag is short for human growth hormone fragment 176-191, the tail end of the growth hormone molecule separated from the rest of it. Full human growth hormone is 191 amino acids long and does several jobs at once; the premise behind this 16-amino-acid piece was that the fat-releasing job sits in the tail and can be used on its own. If you have also come across the name AOD-9604, that is the same compound under its drug-development name: the Australian company Metabolic Pharmaceuticals added one tyrosine to the front of the sequence for stability, called the result AOD-9604, and carried it through six randomized, double-blind, placebo-controlled human trials before the obesity programme was abandoned (Stier 2013). The molecule was later revived under a third name, LAT8881, for nerve-pain research. Vendors often sell HGH Frag 176-191 and AOD-9604 as if they were two different products; the sequence and the intended mechanism are the same, and every human trial in the published literature was run on the tyrosine-modified version rather than on the bare fragment.

• Body-fat reduction, which is the indication the six human obesity trials were built around
• Attempting growth-hormone-style fat release without the rise in insulin-like growth factor 1 that full-length growth hormone causes
• Off-label use during cutting phases alongside diet and training, which is where most present-day demand comes from
• Nerve-pain research under the name LAT8881, a separate programme from the fat-loss claims
• Joint and cartilage interest, which currently rests on animal work rather than on anything measured in people

Picture growth hormone as a long memo with several different instructions on it: release stored fat, grow tissue, push blood sugar up. HGH Frag is a photocopy of the last paragraph only, the one about releasing fat. Because the rest of the memo is missing it does not attach to the growth hormone receptor and does not raise insulin-like growth factor 1, which is the growth signal the full hormone switches on. The catch is that a paragraph taken out of context turned out to be a much fainter instruction in people than the rodent work suggested.

1. Week 1-2The human trials measured blood markers rather than how people felt, so the literature describes no reliable early subjective effect you can expect here.
2. Week 3-4Rodent studies saw reduced weight gain and increased fat oxidation over roughly two to three weeks of daily dosing, but rodent timing does not transfer to people.
3. Week 12One of the six obesity trials ran to about this point. The published record covers tolerability, so there is no peer-reviewed twelve-week fat-loss figure to measure yourself against.
4. Week 24This is as far as any published human dosing went. No approved weight-loss product came out of that programme, which is the single most useful fact about the expected result.
5. Past 24 weeksNo human data exists beyond 24 weeks, so long-term effects are unknown rather than reassuring.

• Upper respiratory tract infection and headache were the adverse events recorded in the placebo-controlled neuropathic pain trial, at rates no different from placebo (5 of 51 on drug versus 6 of 51 on placebo, NCT03865953)
• No serious adverse events occurred in either arm of that trial, and no withdrawal or serious adverse event related to the drug occurred in any of the six obesity trials (Stier 2013)
• No anti-AOD9604 antibodies were detected in the participants selected for antibody testing, and serum insulin-like growth factor 1 did not change (Stier 2013)
• Oral glucose tolerance testing showed no negative effect on carbohydrate metabolism, in contrast to full-length growth hormone (Stier 2013)
• Injection-site reactions are not characterised in the published human trials, because those trials used oral and intravenous dosing rather than the subcutaneous injection used off-label today
• Reviews of self-administered growth-hormone-axis peptides report endocrine and metabolic disturbance, fluid retention, musculoskeletal symptoms and injection-site reactions across that class, and note that rigorous human safety data for the unapproved members of it are scarce (Frontiers in Endocrinology 2026; Sports Medicine 2026)

• You are pregnant, trying to conceive, or breastfeeding; no human reproductive data exists for this fragment
• You have a current or past cancer diagnosis or an unexplained growing lump, which is the standard precaution for anything derived from growth hormone and has not been studied for this fragment
• You compete in a sport that follows the World Anti-Doping Agency code, where growth hormone fragments including AOD-9604 and hGH 176-191 are prohibited at all times
• You are taking it for nerve pain on the strength of the LAT8881 programme; the one randomised, double-blind, placebo-controlled trial in diabetic peripheral neuropathy and post-herpetic neuralgia missed its primary endpoint, minus 0.87 on drug against minus 0.74 on placebo (NCT03865953)
• You are already using AOD-9604. It is the same molecule under a different name, so running both stacks the dose rather than adding a second mechanism
• You are under 18 or still growing
• You are not working with a physician who knows you are using it and can monitor you

• Buying HGH Frag 176-191 and AOD-9604 as though they were two different compounds, or stacking them together. They are the same fragment under different names, so doubling up doubles the dose rather than adding a second mechanism.
• Reading the human trial record as proof of fat loss. Those trials establish tolerability; the published paper reports no weight-loss figures, and when the same molecule was later tested against placebo for a different indication it did not beat placebo (NCT03865953).
• Treating it as a substitute for growth hormone or a growth hormone secretagogue. It does not bind the growth hormone receptor and does not raise insulin-like growth factor 1, so the muscle and recovery effects people associate with growth hormone are not part of it.
• Reconstituting with tap or spring water, or shaking the vial. Use bacteriostatic water, run it slowly down the inside wall, and swirl rather than shake so the peptide is not sheared.
• Leaving reconstituted vials on the counter or stretching one vial over months. Keep the dry powder cold and dark, refrigerate after reconstitution, and discard on the timeline your pharmacist gives you.